New Vaccine Candidate Against COVID-19 To Be Developed By Bharat Biotech and Thomas Jefferson University


News provided by

Independent Tech & news media Writer

May 20, 2020, 09:21 EST


Elkland, United States, May 20, 2020, 09:21 /Comserve / -- Hyderabad, India and Philadelphia, 20th May 2020: Bharat Biotech, known as a global leader and vaccine innovator, along with Thomas Jefferson University of Philadelphia

Image placeholder

Hyderabad, India and Philadelphia, 20th May 2020: Bharat Biotech, known as a global leader and vaccine innovator, along with Thomas Jefferson University of Philadelphia announced that they have signed an exclusive deal for the development of a new vaccine candidate for COVID-19 invented at Jefferson.

COVID-19 or the novel coronavirus was first detected in Wuhan, China. A pneumonia of unknown cause, the disease was first reported to the country office of World Health Organization in China on 31st of December 2019. Since then, the pandemic disease spread worldwide, resulting in the declaration of a Public Health Emergency of International Concern by the WHO.

By the use of an existing deactivated rabies vaccine as a vehicle for proteins of coronavirus, the novel vaccine was developed. The deactivated rabies vaccine was used as a carrier because the carrier vaccine is known to produce a strong immune response and is further approved for the whole population. This also included children and pregnant women.

One of the coronavirus experts of The Jefferson Vaccine Institute, Prof. Schnell, who also chairs the Department of Microbiology and Immunology of the Institute, stated that the partnership between their team and Bharat Biotech is anticipated to accelerate the vaccine candidate throughout the next developmental phases. He further stated that both the teams together would be able to complete animal testing and would further move to the phase 1 of clinical trials.

On the other hand, the CEO of Bharat Biotech, Dr. Krishna Mohan, stated that his company is pleased to collaborate along with Thomas Jefferson, USA, to meet the increasing demand for an effective vaccine for COVID-19. He further stated that he and his team is excited about the inactivated rabies vector platform technology as the basic proof of concept has been established while using it for other pandemic infectious diseases.

Independent Tech & news media Writer


For more information, please contact:

Marlin Bode

Independent Tech & news media Writer
Email: bodemarlin@gmail.com
Tel: +1 814-302-1499

Related Links
https://www.comserveonline.com/



Also from this source


“CoreMedia Content Cloud” – Commerce B2B Connector on Salesforce AppExchange has Been Launched by CoreMedia

CoreMedia Content Cloud, a Commerce B2B Connector is launched by CoreMedia on Salesforce AppExchange


Casio G-SHOCK Comes up with its First Set of Product Releases for 2020

The announcement of a brand new set of timepieces in model GM6900 was made by Casio G-SHOCK as its f